Contact

“Health as growth motor: from cost factor to value creation” Die Zeit, December 2025 (in German) Read Article “CPHI 2025: ‘handprint’ metric bridges pharma sustainability and economic value” Pharmaceutical Technology, November 2025 Read Article “Healthy returns: Why Europe must treat healthcare as an investment, not a cost” Euronews, October 2025 Watch discussion “Baby boomers retire: Labor market threatened by brain drain” Frankfurter Rundschau, September 2025 Read Article “Health to combat the economic downturn” Gesundheit + Gesellschaft (AOK), May 2025 Read Article “Account for sustainability financially, point by point” GREEN.WORKS, December 2024 Read Article Should weight-loss medications be covered by health insurance? Südwest Presse, October 2024 Read Article In Interview: Dr. Müller on the return on investment of better health Health&Care Management, July 2023 Read Article EU Regulation: Why are medical
devices disappearing from the market? ARD Plusminus, February 2023 Watch Interview Automotive industry in a state of flux SWR Aktuell, July 2023 Read Article

Expert list

News

Events

Masterclass: Outperform Your Sector – Using Benchmarks for Strategic Decision-Making
 May 28, 2025 Watch Recording Masterclass: Measure Your Company’s Supply Chain Impact in 3 Simple Steps Using WISIT March 13, 2025 Watch Recording

Upcoming Events

7. – 10. Mai 2023

ISPOR

Boston

Mehr

12. Mai 2023

Veranstaltung am Tag der Pflegenden

Berlin

Mehr

Press Releases

WifOR Institute Co-Launches G20 & G7 Toolkit for Strategic Health Investments at H20 Summit in Geneva

Read

New Country and Sector Benchmarks Offer Guidance for Effective Policy and Business Strategies

Read

The Lancet Oncology: WifOR Institute Calculates $725M in Economic Potential from Expanded Cancer Treatment Access

Read

Leading impact valuation providers team up to democratize access to Value Factors

Read

Early Intensified Treatment Cuts Type 2 Diabetes Burden by USD 23 Million in Korea

Read

WifOR has published its Impact Valuation factors

Read

WifOR publication enables Impact Measurement and Valuation for financial institutions and investment portfolios

Read

WifOR study in Journal of Medical Economics: Omalizumab can reduce the burden of Pollinosis by USD 728 million in Japan

Read

WifOR study: How can new treatment options reduce the socioeconomic impact of migraine?

Read

You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

Unblock content
More Information
Katja Wies
Marketing & Communications Lead

katja.wies@wifor.com

+49 151 158 379 42

Contact